Clinical Trials
2
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms
Phase 2
Completed
- Conditions
- Gastroesophageal Reflux
- Interventions
- Drug: VECAM 40/300
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Vecta Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT01059383
- Locations
- 🇺🇸
Clinical Applications Laboratories Inc., San Diego, California, United States
🇺🇸Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States
Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- Vecta Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT00818870
- Locations
- 🇺🇸
Clinical Applications Laboratories Inc., San Diego, California, United States
News
No news found